| Q94352185 | Q94352185 |
| Q53126609 | 18 F-fluorodeoxyglucose positron emission tomography-computed tomography for preoperative lymph node staging in patients undergoing radical cystectomy for bladder cancer: a prospective study. |
| Q44327010 | 18F-fluorodeoxyglucose--positron emission tomography/computed tomography aids staging and predicts mortality in patients with muscle-invasive bladder cancer |
| Q30485127 | A 20 gene model for predicting nodal involvement in bladder cancer patients with muscle invasive tumors |
| Q40954926 | A Case Report Demonstrating the Potential Clinical Benefit of Exhaustive Molecular Profiling in an Aggressive Muscle-Invasive High-Grade Metastatic Urothelial Carcinoma |
| Q92307715 | A Novel Biomarker Based on miRNA to Predict the Prognosis of Muscle-Invasive Bladder Urothelial Carcinoma |
| Q38885025 | A Systematic Review of Ileal Conduit and Neobladder Outcomes in Primary Bladder Cancer |
| Q41255730 | A case of isolated rectal recurrence of muscle invasive bladder cancer |
| Q61447102 | A multi-institutional study of bladder-preserving therapy for stage II-IV bladder cancer: A Korean Radiation Oncology Group Study (KROG 14-16) |
| Q45179878 | A new prognostic model for cancer-specific survival after radical cystectomy including pretreatment thrombocytosis and standard pathological risk factors |
| Q33729078 | Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity |
| Q43917433 | Accurate preoperative prediction of non-organ-confined bladder urothelial carcinoma at cystectomy |
| Q94599582 | Acetyl-CoA synthetase 3 promotes bladder cancer cell growth under metabolic stress |
| Q38131409 | Alterations of DNA methylome in human bladder cancer. |
| Q37290684 | An Epigenomic Approach to Improving Response to Neoadjuvant Cisplatin Chemotherapy in Bladder Cancer |
| Q36285089 | An Evaluation of the Timing of Surgical Complications Following Radical Cystectomy: Data From the American College of Surgeons National Surgical Quality Improvement Program |
| Q35929279 | Anterior urethra sparing cystoprostatectomy for bladder cancer: a 10-year, single center experience. |
| Q35205137 | Are urothelial carcinomas of the upper urinary tract a distinct entity from urothelial carcinomas of the urinary bladder? Behavior of urothelial carcinoma after radical surgery with respect to anatomical location: a case control study |
| Q35739387 | Assess the expression of ubiquitin specific protease USP2a for bladder cancer diagnosis |
| Q47120808 | Association of MMP-2, RB and PAI-1 with decreased recurrence-free survival and overall survival in bladder cancer patients |
| Q89586501 | Association of cancer progression with elevated expression of programmed cell death protein 1 ligand 1 by upper tract urothelial carcinoma and increased tumor-infiltrating lymphocyte density |
| Q38053535 | Bcl-2 family of proteins as therapeutic targets in genitourinary neoplasms. |
| Q28079221 | Beyond penile cancer, is there a role for sentinel node biopsy in urological malignancies? |
| Q35671292 | Biomarkers for prognosis and treatment selection in advanced bladder cancer patients |
| Q28072814 | Bladder Sparing Approaches for Muscle-Invasive Bladder Cancers |
| Q37216041 | Bladder cancer discussed on the internet: a systematic analysis of gender differences of initial posters on an online discussion board |
| Q30683510 | Bladder cancer--the neglected tumor: a descriptive analysis of publications referenced in MEDLINE and data from the register ClinicalTrials.gov |
| Q36108115 | Bladder cancer: a simple model becomes complex |
| Q33928633 | Bladder preservation with brachytherapy compared to cystectomy for T1-T3 muscle-invasive bladder cancer: a systematic review |
| Q40609183 | Budget impact of incorporating one instillation of hexaminolevulinate hydrochloride blue-light cytoscopy in transurethral bladder tumour resection for patients with non-muscle-invasive bladder cancer in Sweden |
| Q60622169 | Cancer-specific mortality following radical cystectomy for bladder cancer with lymph node involvement: impact of pathologic disease features and adjuvant chemotherapy |
| Q26860953 | Cell adhesion and urothelial bladder cancer: the role of cadherin switching and related phenomena |
| Q38808040 | Challenges with in vitro and in vivo experimental models of urinary bladder cancer for novel drug discovery. |
| Q34788410 | Chemokine (C-X-C) ligand 1 (CXCL1) protein expression is increased in aggressive bladder cancers |
| Q92198278 | CircRNA circPDSS1 promotes bladder cancer by down-regulating miR-16 |
| Q36238822 | Clinical Significance of ErbB Receptor Family in Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-Analysis |
| Q86897782 | Clinical and pathological nodal staging score for urothelial carcinoma of the bladder: an external validation |
| Q41471527 | Clinical and therapeutic factors associated with adverse pathological outcomes in clinically node-negative patients treated with neoadjuvant cisplatin-based chemotherapy and radical cystectomy |
| Q39855461 | Clinical role of additional adjuvant chemotherapy in patients with locally advanced urothelial carcinoma following neoadjuvant chemotherapy and cystectomy. |
| Q35533836 | Clinical, demographic and histopathological prognostic factors for urothelial carcinoma of the bladder |
| Q64057219 | Collagen-rich airway smooth muscle cells are a metastatic niche for tumor colonization in the lung |
| Q53994895 | Combining smoking information and molecular markers improves prognostication in patients with urothelial carcinoma of the bladder. |
| Q40381359 | Comparative analysis of the effect of prostatic invasion patterns on cancer-specific mortality after radical cystectomy in pT4a urothelial carcinoma of the bladder |
| Q36589338 | Comparison beetwen open and laparoscopic radical cistectomy in a Latin American reference center: perioperative and oncological results |
| Q53059593 | Comparison of the EORTC tables and the EAU categories for risk stratification of patients with nonmuscle-invasive bladder cancer. |
| Q37105651 | Complications and oncologic outcomes following robot-assisted radical cystectomy: What is the real benefit? |
| Q57582151 | Concordance and Clinical Significance of Uncommon Variants of Bladder Urothelial Carcinoma in Transurethral Resection and Radical Cystectomy Specimens |
| Q38206405 | Contemporary gender-specific outcomes in Germany after radical cystectomy for bladder cancer |
| Q95300977 | Critical role of SOX2-IGF2 signaling in aggressiveness of bladder cancer |
| Q50675628 | Curcumin inhibits urothelial tumor development by suppressing IGF2 and IGF2-mediated PI3K/AKT/mTOR signaling pathway. |
| Q27027719 | Current and potential applications of host-defense peptides and proteins in urology |
| Q38180489 | Current evidence for transurethral en bloc resection of non-muscle-invasive bladder cancer |
| Q38183895 | Current indications and results of orthotopic ileal neobladder for bladder cancer. |
| Q37962658 | Current management of muscle-invasive bladder cancer |
| Q50109278 | Current status of robotic surgery in urology |
| Q38102879 | DNA methylation-based biomarkers in bladder cancer |
| Q42970925 | Delivering high-quality care to patients with muscle-invasive bladder cancer: Insights from routine practice in Ontario |
| Q36277837 | Denosumab: a new option in the treatment of bone metastases from urological cancers |
| Q38843266 | Detecting asymptomatic recurrence after radical cystectomy contributes to better prognosis in patients with muscle-invasive bladder cancer |
| Q97527356 | Determinants of neoadjuvant chemotherapy use in muscle-invasive bladder cancer |
| Q44042378 | Development and external validation of lymph node density cut-off points in prospective series of radical cystectomy and pelvic lymph node dissection |
| Q50225627 | Development of a Preoperative Nomogram Incorporating Biomarkers of Systemic Inflammatory Response to Predict Nonorgan-confined Urothelial Carcinoma of the Bladder at Radical Cystectomy. |
| Q38220668 | Diagnosis and management of intradiverticular bladder tumours |
| Q33688951 | Diagnosis of bladder cancer and prediction of survival by urinary metabolomics |
| Q38115193 | Diagnostic utility of androgen receptor expression in discriminating poorly differentiated urothelial and prostate carcinoma |
| Q51150690 | Do blood groups have effect on prognosis of patients undergoing radical cystectomy? |
| Q45731475 | Do differences in clinical symptoms and referral patterns contribute to the gender gap in bladder cancer? |
| Q41066349 | Downregulation of DOCK1 sensitizes bladder cancer cells to cisplatin through preventing epithelial-mesenchymal transition |
| Q35806000 | Drug-Resistant Urothelial Cancer Cell Lines Display Diverse Sensitivity Profiles to Potential Second-Line Therapeutics. |
| Q37681730 | EIF5A2 predicts outcome in localised invasive bladder cancer and promotes bladder cancer cell aggressiveness in vitro and in vivo |
| Q28082054 | EZH2 in Bladder Cancer, a Promising Therapeutic Target |
| Q50240417 | Editorial Comment to Robotic transmural ablation of bladder tumors using high-intensity focused ultrasound: Experimental study |
| Q87414334 | Editorial comment |
| Q53085995 | Effect of diabetes mellitus and metformin use on oncologic outcomes of patients treated with radical cystectomy for urothelial carcinoma. |
| Q34337059 | Efficacy of robot-assisted radical cystectomy (RARC) in advanced bladder cancer: results from the International Radical Cystectomy Consortium (IRCC) |
| Q27320007 | Endoscopic Gold Fiducial Marker Placement into the Bladder Wall to Optimize Radiotherapy Targeting for Bladder-Preserving Management of Muscle-Invasive Bladder Cancer: Feasibility and Initial Outcomes |
| Q38842793 | Enumerating pelvic recurrence following radical cystectomy for bladder cancer: A Canadian multi-institutional study. |
| Q92072853 | Epigenetics of Bladder Cancer: Where Biomarkers and Therapeutic Targets Meet |
| Q47956395 | Evaluation of robot-assisted laparoscopic versus open cystectomy and effect of carbon dioxide-pneumoperitoneum on histopathological findings in ureteroenteric anastomoses: results from an experimental randomized porcine study. |
| Q43900072 | Evidence from the 'PROspective MulticEnTer RadIcal Cystectomy Series 2011 (PROMETRICS 2011)' study: how are preoperative patient characteristics associated with urinary diversion type after radical cystectomy for bladder cancer? |
| Q53140967 | Expression of TIP60 (tat-interactive protein) and MRE11 (meiotic recombination 11 homolog) predict treatment-specific outcome of localised invasive bladder cancer. |
| Q58090682 | Expression of TOMM34 and Its Clinicopathological Correlations in Urothelial Carcinoma of the Bladder |
| Q46897455 | Extent of lymph node dissection and recurrence-free survival after radical cystectomy: a meta-analysis |
| Q44097656 | External validation of extranodal extension and lymph node density as predictors of survival in node-positive bladder cancer after radical cystectomy |
| Q51152269 | External validation of preoperative and postoperative nomograms for prediction of cancer-specific survival, overall survival and recurrence after robot-assisted radical cystectomy for urothelial carcinoma of the bladder. |
| Q46543034 | Factors predicting incisional surgical site infection in patients undergoing open radical cystectomy for bladder cancer. |
| Q48143698 | Feasibility of radical cystectomy in exclusive spinal and/or epidural anaesthesia |
| Q36898795 | Fine Needle Aspiration Cytology Diagnosis of an Urachal Adenocarcinoma |
| Q50458622 | Fluorescence-enhanced robotic radical cystectomy using unconjugated indocyanine green for pelvic lymphangiography, tumor marking, and mesenteric angiography: the initial clinical experience |
| Q92645224 | Focal adhesion kinase (FAK) is associated with poor prognosis in urinary bladder carcinoma |
| Q37662246 | Foxp3 enhances HIF-1α target gene expression in human bladder cancer through decreasing its ubiquitin-proteasomal degradation |
| Q47259653 | Gender-dependent cancer-specific survival following radical cystectomy |
| Q44793009 | Gender-specific differences in cancer-specific survival after radical cystectomy for patients with urothelial carcinoma of the urinary bladder in pathologic tumor stage T4a. |
| Q54371991 | Gene expression and prognosis in bladder cancer--real progress? Editorial on 'S100A9 and EGFR gene signatures predict disease progression in muscle invasive bladder cancer patients after chemotherapy'. |
| Q33470789 | Health-Related Quality of Life after Radical Cystectomy: A Cross Sectional Study with Matched Pair Analysis on Ileal Conduit Versus Ileal Orthotopic Neobladder Diversion |
| Q34184763 | High expression of GEM and EDNRA is associated with metastasis and poor outcome in patients with advanced bladder cancer |
| Q40121054 | High expression of constitutive photomorphogenic 1 (COP1) is associated with poor prognosis in bladder cancer |
| Q36893027 | Histone deacetylase inhibitor-induced cell death in bladder cancer is associated with chromatin modification and modifying protein expression: A proteomic approach |
| Q37665276 | Hypoxia enhances the malignant nature of bladder cancer cells and concomitantly antagonizes protein O-glycosylation extension |
| Q38556960 | Imaging muscle-invasive and metastatic urothelial carcinoma. |
| Q37137381 | Immunotherapy for urothelial carcinoma: current status and perspectives |
| Q53104789 | Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle. |
| Q35137483 | Impact of EZH2 polymorphisms on urothelial cell carcinoma susceptibility and clinicopathologic features |
| Q43569010 | Impact of peri-operative blood transfusion on the outcomes of patients undergoing radical cystectomy for urothelial carcinoma of the bladder |
| Q45793333 | Impact of preoperative immunonutrition on morbidity following cystectomy for bladder cancer: a case-control pilot study |
| Q44579463 | Imperative cystectomy in patients at risk. Ileal conduit or ureterocutaneostomy? |
| Q35406622 | Increased expression of SPRY4-IT1 predicts poor prognosis and promotes tumor growth and metastasis in bladder cancer |
| Q50448025 | Increased miR-141 expression is associated with diagnosis and favorable prognosis of patients with bladder cancer |
| Q38027501 | Inflammatory pathways as promising targets to increase chemotherapy response in bladder cancer |
| Q36545877 | Inhibiting bladder tumor growth with a cell penetrating R11 peptide derived from the p53 C-terminus |
| Q91595589 | Inhibition of a G9a/DNMT network triggers immune-mediated bladder cancer regression |
| Q33755719 | Inhibition of autophagy potentiates atorvastatin-induced apoptotic cell death in human bladder cancer cells in vitro |
| Q35040383 | Inhibitory role of the small leucine-rich proteoglycan biglycan in bladder cancer |
| Q37996803 | Interobserver variability limits exact preoperative staging by computed tomography in bladder cancer. |
| Q40319613 | Intestinal neobladder fistula after radical cystectomy and orthotopic ileal neobladder |
| Q38635958 | Is Health-Related Quality of Life after Radical Cystectomy Using Validated Questionnaires Really Better in Patients with Ileal Orthotopic Neobladder Compared to Ileal Conduit: A Meta-Analysis of Retrospective Comparative Studies |
| Q44628922 | Is it oncologically safe performing simultaneous transurethral resection of the bladder and prostate? A meta-analysis on 1,234 patients. |
| Q38947153 | KLF8 is required for bladder cancer cell proliferation and migration |
| Q53124503 | Laparoscopic pelvic lymph node dissection system based on preoperative primary tumour stage (T stage) by computed tomography in urothelial bladder cancer: results of a single-institution prospective study. |
| Q57110953 | Laparoscopic radical cystectomy with extracorporeal ileal neobladder for muscle-invasive urothelial carcinoma of the bladder: technique and short-term outcomes |
| Q42660056 | Laparoscopic radical cystectomy: initial experience using the single-incision triangulated umbilical surgery (SITUS) technique |
| Q58734645 | Lapatinib, a Dual Inhibitor of Epidermal Growth Factor Receptor (EGFR) and HER-2, Enhances Radiosensitivity in Mouse Bladder Tumor Line-2 (MBT-2) Cells In Vitro and In Vivo |
| Q39003138 | Lessons from 151 ureteral reimplantations for postcystectomy ureteroenteric strictures: A single-center experience over a decade. |
| Q44202702 | Lipiodol as a fiducial marker for image-guided radiation therapy for bladder cancer |
| Q42640085 | Long-term evaluation of oncologic and functional outcomes after laparoscopic open-assisted radical cystectomy: a matched-pair analysis. |
| Q50626554 | Looking forward, looking back-10 years in urology. |
| Q40839199 | Loss of DAB2IP expression in human urothelial carcinoma is associated with poorer recurrence-free survival |
| Q58093528 | Loss of GAS5 tumour suppressor lncRNA: an independent molecular cancer biomarker for short-term relapse and progression in bladder cancer patients |
| Q56835133 | Loss of expression of the tumour suppressor geneAIMP3predicts survival following radiotherapy in muscle-invasive bladder cancer |
| Q36085868 | Loss of heterozygosis on chromosome 18q21-23 and muscle-invasive bladder cancer natural history |
| Q39209553 | Loss of nuclear prothymosin-α expression is associated with disease progression in human superficial bladder cancer |
| Q41560984 | Lymph node counts are valid indicators of the quality of surgical care in bladder cancer: a population-based study. |
| Q41706346 | Lymph node density in muscle-invasive transitional cell carcinoma of the urinary bladder; De novo versus progressive disease |
| Q38124003 | Lymph node dissection during radical cystectomy for bladder cancer treatment: considerations on relevance and extent |
| Q64261127 | Machine learning models for predicting post-cystectomy recurrence and survival in bladder cancer patients |
| Q97542139 | Magnetism in drug delivery: The marvels of iron oxides and substituted ferrites nanoparticles |
| Q53592801 | Maintenance monotherapy with gemcitabine after standard platinum-based chemotherapy in patients with advanced urothelial cancer. |
| Q53060401 | Malignant ureteroenteric anastomotic stricture following radical cystectomy with urinary diversion: Patterns, risk factors, and outcomes. |
| Q38063557 | Management of local recurrences in the irradiated bladder: a systematic review |
| Q47888544 | MicroRNA-154 as a prognostic factor in bladder cancer inhibits cellular malignancy by targeting RSF1 and RUNX2. |
| Q35747341 | MicroRNA-1826 targets VEGFC, beta-catenin (CTNNB1) and MEK1 (MAP2K1) in human bladder cancer |
| Q42668217 | Minimally invasive cystectomy is associated with improved perioperative patient safety outcomes compared with open cystectomy in a national cohort |
| Q93182648 | Molecular footprints of muscle-invasive bladder cancer in smoking and nonsmoking patients |
| Q38248822 | Molecular markers for urothelial bladder cancer prognosis: toward implementation in clinical practice |
| Q36823607 | Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer |
| Q43913506 | Muscle invasive bladder cancer after radical cystectomy. Prognostic factors of adjuvant chemotherapy |
| Q57073248 | Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer and Its Impact on Surgical Morbidity and Oncological Outcomes: A Real-World Experience |
| Q33662842 | Neoadjuvant chemotherapy for bladder cancer does not increase risk of perioperative morbidity |
| Q33758673 | Neoadjuvant chemotherapy use in bladder cancer: a survey of current practice and opinions |
| Q37305943 | New therapeutic targets in the management of urothelial carcinoma of the bladder |
| Q34506226 | Oncogenic miRNA-182-5p targets Smad4 and RECK in human bladder cancer |
| Q37455252 | Optimizing care and outcomes of patients with muscle-invasive bladder cancer |
| Q91474385 | Overexpressed miR-200a promotes bladder cancer invasion through direct regulating Dicer/miR-16/JNK2/MMP-2 axis |
| Q36574137 | Overexpression of RNF2 Is an Independent Predictor of Outcome in Patients with Urothelial Carcinoma of the Bladder Undergoing Radical Cystectomy |
| Q36654987 | PET/CT and MRI in Bladder Cancer |
| Q44883575 | Pathological factors associated with survival benefit from adjuvant chemotherapy (ACT): a population-based study of bladder cancer |
| Q38691499 | Patient-centered risk stratification of disposition outcomes following radical cystectomy |
| Q84916976 | Patterns of local recurrence after radical cystectomy in a contemporary series of patients with muscle-invasive bladder cancer |
| Q37053765 | Pelvic Lymph Node Dissection may be Limited on the Contralateral Side in Strictly Unilateral Bladder Cancer without Compromising Oncological Radicality |
| Q39078873 | Perioperative chemotherapy in upper tract urothelial carcinoma: a comprehensive review. |
| Q39459198 | Pharmacogenomic considerations in the treatment of muscle-invasive bladder cancer |
| Q38325864 | Pharmacokinetic and toxicity considerations in the use of neoadjuvant chemotherapy for bladder cancer |
| Q44017338 | Pharmacological therapy of urogenital cancer: rational routine diagnostic imaging |
| Q38816754 | Phenotype plasticity rather than repopulation from CD90/CK14+ cancer stem cells leads to cisplatin resistance of urothelial carcinoma cell lines |
| Q44727503 | Photodynamic therapy of bladder cancer. A new option |
| Q34581376 | Plasmacytoid variant of bladder cancer defines patients with poor prognosis if treated with cystectomy and adjuvant cisplatin-based chemotherapy. |
| Q37244332 | Polymorphisms in the XRCC1 gene modify survival of bladder cancer patients treated with chemotherapy |
| Q51269681 | Population-based trends in urinary diversion among patients undergoing radical cystectomy for bladder cancer. |
| Q37393594 | Potential survival benefit of anti-apoptosis protein: survivin-derived peptide vaccine with and without interferon alpha therapy for patients with advanced or recurrent urothelial cancer--results from phase I clinical trials |
| Q57643630 | Potentially clinically relevant prostate cancer is found more frequently after complete than after partial histopathological processing of radical cystoprostatectomy specimens |
| Q40368151 | Predicting response to neoadjuvant chemotherapy in bladder cancer: controversies remain with genomic DNA sequencing |
| Q36040421 | Prediction of non-muscle invasive bladder cancer outcomes assessed by innovative multimarker prognostic models |
| Q46489162 | Predictors of cancer-specific mortality after disease recurrence following radical cystectomy |
| Q41127920 | Preoperative anemia is associated with adverse outcome in patients with urothelial carcinoma of the bladder following radical cystectomy |
| Q44685063 | Preoperative risk factors related to bladder cancer rehabilitation: a registry study |
| Q92440926 | Prognostic Significance of Lymphocyte Infiltration and a Stromal Immunostaining of a Bladder Cancer Associated Diagnostic Panel in Urothelial Carcinoma |
| Q35891117 | Prognostic factors for conditional survival in patients with muscle-invasive urothelial carcinoma of the bladder treated with radical cystectomy |
| Q34492819 | Prognostic value of serum nicotinamide phosphoribosyltransferase in patients with bladder cancer. |
| Q48501255 | Prospective Evaluation of Nutritional Factors to Predict the Risk of Complications for Patients Undergoing Radical Cystectomy: A Cohort Study |
| Q44293813 | Prospective evaluation of a preoperative biomarker panel for prediction of upstaging at radical cystectomy |
| Q88149718 | Prospective evaluation of diffusion-weighted MRI of the bladder as a biomarker for prediction of bladder cancer aggressiveness |
| Q92866121 | QKI-6 inhibits bladder cancer malignant behaviours through down-regulating E2F3 and NF-κB signalling |
| Q36691496 | Quality of life in women undergoing urinary diversion for bladder cancer: results of a multicenter study among long-term disease-free survivors |
| Q30383168 | Quantitative ultrasound imaging of therapy response in bladder cancer in vivo. |
| Q64945349 | Rab11 Functions as an Oncoprotein via Nuclear Factor kappa B (NF-κB) Signaling Pathway in Human Bladder Carcinoma. |
| Q41464467 | Radical cystectomy and adjuvant chemotherapy for bladder cancer in the elderly: a population-based study |
| Q38176436 | Radical cystectomy and the implications of comorbidity |
| Q46344162 | Radical cystectomy with super-extended lymphadenectomy: impact of separate vs en bloc lymph node submission on analysis and outcomes. |
| Q30240141 | Radical cystectomy: do we need standardization? |
| Q38244318 | Radical trimodality therapy for patients with locally advanced bladder cancer: The British Columbia Cancer Agency experience |
| Q39112866 | Radiosensitisation of bladder cancer cells by panobinostat is modulated by Ku80 expression. |
| Q35993984 | Re: The feasibility of radical cystectomy in elderly patients |
| Q35606282 | Readmission after robot-assisted radical cystectomy: outcomes and predictors at 90-day follow-up |
| Q38913953 | Redefining the implications of nasogastric tube placement following radical cystectomy in the alvimopan era. |
| Q37342899 | Regional differences in practice patterns and outcomes in patients treated with radical cystectomy in a universal healthcare system |
| Q43557462 | Reporting trends and prognostic significance of lymphovascular invasion in muscle-invasive urothelial carcinoma: a population-based study |
| Q57113884 | Retroperitoneal hernia following radical cystectomy: case report |
| Q38833958 | Retrospective analysis of a surgical innovation using the IDEAL framework: radical cystectomy with epidural anaesthesia |
| Q58788944 | Rewiring of cisplatin-resistant bladder cancer cells through epigenetic regulation of genes involved in amino acid metabolism |
| Q53840977 | Risk factors of hospital readmission after radical cystectomy and urinary diversion: analysis of a large contemporary series. |
| Q41462223 | Risk stratification for locoregional recurrence after radical cystectomy for urothelial carcinoma of the bladder |
| Q36419132 | Risk stratification of pT1-3N0 patients after radical cystectomy for adjuvant chemotherapy counselling |
| Q42371550 | Risk-stratified surveillance and cost effectiveness of follow-up after radical cystectomy in patients with muscle-invasive bladder cancer |
| Q55334154 | Risk-stratified surveillance protocol improves cost-effectiveness after radical nephroureterectomy in patients with upper tract urothelial carcinoma. |
| Q33995446 | Robot-assisted radical cystectomy with intracorporeal neobladder diversion: The Karolinska experience |
| Q27014781 | Robotic versus open radical cystectomy: an updated systematic review and meta-analysis |
| Q38091333 | Robotic-assisted laparoscopic radical cystectomy: history, techniques and outcomes |
| Q48192956 | Robotic-assisted versus open radical cystectomy in bladder cancer: A meta-analysis of four randomized controlled trails. |
| Q30839472 | Role of diffusion-weighted magnetic resonance imaging as an imaging biomarker of urothelial carcinoma |
| Q42451041 | Role of fluorodeoxyglucose positron emission tomography (FDG PET)-computed tomography (CT) in the staging of bladder cancer |
| Q91813181 | Role of gemcitabine and cisplatin as neoadjuvant chemotherapy in muscle invasive bladder cancer: Experience over the last decade |
| Q49588479 | Role of lncRNA PTENP1 in tumorigenesis and progression of bladder cancer and the molecular mechanism |
| Q38003684 | Role of lymphadenectomy in the management of urothelial carcinoma of the bladder and the upper urinary tract |
| Q38002448 | Role of magnetic resonance imaging in bladder cancer: current status and emerging techniques |
| Q50871940 | SNAI1 protein expression is an independent negative prognosticator in muscle-invasive bladder cancer. |
| Q43605987 | Second-line chemotherapy for advanced bladder cancer: a survey of current UK practice. |
| Q38255032 | Selective organ preservation for the treatment of muscle-invasive transitional cell carcinoma of the bladder: a review of current and future perspectives |
| Q27027693 | Sentinel lymph node biopsy in bladder cancer: Systematic review and technology update |
| Q30870825 | Significance of lymphovascular invasion in organ-confined, node-negative urothelial cancer of the bladder: data from the prospective p53-MVAC trial. |
| Q36591517 | Silencing of mutant p53 by siRNA induces cell cycle arrest and apoptosis in human bladder cancer cells |
| Q38156189 | Small cell carcinoma of the urinary bladder: a contemporary review with a special focus on bladder-sparing treatments |
| Q52640448 | Smoking intensity and bladder cancer aggressiveness at diagnosis. |
| Q45083997 | Stage-specific impact of extended versus standard pelvic lymph node dissection in radical cystectomy |
| Q53183754 | Staging of muscle-invasive bladder cancer: can computerized tomography help us to decide on local treatment? |
| Q26774347 | Standard cystectomy fits all: truth or myth? |
| Q30396120 | Standards of the Polish Ultrasound Society - update. Ultrasound examination of the kidneys, ureters and urinary bladder. |
| Q37003991 | Suboptimal use of neoadjuvant chemotherapy in radical cystectomy patients: A population-based study |
| Q91719984 | Surgical approach as a determinant factor of clinical outcome following radical cystectomy: Does Enhanced Recovery After Surgery (ERAS) level the playing field? |
| Q27013035 | Surgical resection of urological tumor metastases following medical treatment |
| Q91045679 | Systematic chemical screening identifies disulfiram as a repurposed drug that enhances sensitivity to cisplatin in bladder cancer: a summary of preclinical studies |
| Q36728287 | Targeted p53 activation by saRNA suppresses human bladder cancer cells growth and metastasis |
| Q38090926 | Targeting GRPR in urological cancers--from basic research to clinical application |
| Q35050111 | Targeting plasminogen activator inhibitor-1 inhibits angiogenesis and tumor growth in a human cancer xenograft model |
| Q38534167 | Targeting the VEGF pathway in metastatic bladder cancer |
| Q47257003 | Targeting urothelial carcinoma cells by combining cisplatin with a specific inhibitor of the autophagy-inducing class III PtdIns3K complex. |
| Q37530349 | The Role of Transurethral Resection in Trimodal Therapy for Muscle-Invasive Bladder Cancer |
| Q86507886 | The conundrum of prostatic urethral involvement |
| Q44321234 | The effects of a physical exercise programme after radical cystectomy for urinary bladder cancer. A pilot randomized controlled trial |
| Q37932541 | The enlightenment of bladder cancer treatment: origin and progress of photodynamic diagnosis |
| Q49189959 | The global epidemiology of bladder cancer: a joinpoint regression analysis of its incidence and mortality trends and projection. |
| Q60054615 | The impact of patient-related nonmodifiable factors on perioperative outcomes following radical cystectomy with enhanced recovery protocol |
| Q35683471 | The long noncoding RNA HOTAIR has tissue and cell type-dependent effects on HOX gene expression and phenotype of urothelial cancer cells |
| Q43770148 | The number of nodes removed as well as the template of the dissection is independently correlated to cancer-specific survival after radical cystectomy for muscle-invasive bladder cancer |
| Q53327091 | The prognostic role of pre-cystectomy hemoglobin levels in patients with invasive bladder cancer. |
| Q38211078 | The role of inflammation in bladder cancer |
| Q53259983 | The small conductance calcium-activated potassium channel 3 (SK3) is a molecular target for Edelfosine to reduce the invasive potential of urothelial carcinoma cells. |
| Q38099237 | The survival benefit of lymph node dissection at the time of removal of kidney, prostate and urothelial carcinomas: what is the evidence? |
| Q35096821 | Thulium:yttrium-aluminum-garnet laser for en bloc resection of bladder cancer: clinical and histopathologic advantages |
| Q35905142 | Trends in the Use of Chemotherapy before and after Radical Cystectomy in Patients with Muscle-invasive Bladder Cancer in Korea. |
| Q47211582 | Trends in urinary diversion after radical cystectomy for urothelial carcinoma. |
| Q39447197 | Tumor suppressor microRNA-493 decreases cell motility and migration ability in human bladder cancer cells by downregulating RhoC and FZD4. |
| Q43717784 | Uncovering the clinical utility of miR-143, miR-145 and miR-224 for predicting the survival of bladder cancer patients following treatment |
| Q36024243 | Up-regulation of long non-coding RNA PANDAR is associated with poor prognosis and promotes tumorigenesis in bladder cancer |
| Q36171243 | Update on the management of invasive bladder cancer 2012. |
| Q54198749 | Upregulation of the long noncoding RNA HOTAIR predicts recurrence in stage Ta/T1 bladder cancer. |
| Q37726904 | Uptake of neoadjuvant chemotherapy for invasive bladder cancer |
| Q35993949 | Ureterocutaneostomy: for whom and when? |
| Q38630083 | Urethral recurrence after cystectomy: current preventative measures, diagnosis and management |
| Q37558983 | Urinary EpCAM in urothelial bladder cancer patients: characterisation and evaluation of biomarker potential |
| Q39189375 | Urinary bladder cancer treated with radical cystectomy: perioperative parameters and early complications prospectively registered in a national population-based database. |
| Q38240134 | Urinary bladder radiotherapy-related chondroblastic osteosarcoma: Rare case report and review of literature |
| Q38833996 | Urothelial Cancer: Inflammatory Mediators and Implications for Immunotherapy. |
| Q37944437 | Urothelial carcinoma of the bladder: definition, treatment and future efforts |
| Q53032143 | Utilisation of preoperative imaging for muscle-invasive bladder cancer: a population-based study. |
| Q34579038 | Validation and clinicopathologic associations of a urine-based bladder cancer biomarker signature |
| Q36686671 | Value of urinary topoisomerase-IIA cell-free DNA for diagnosis of bladder cancer |
| Q64927399 | Vitamin D3 enhances the response to cisplatin in bladder cancer through VDR and TAp73 signaling crosstalk. |
| Q49473636 | Years of life lost due to bladder cancer among the inhabitants of Poland in the years 2000 to 2014. |
| Q83335539 | [Advanced bladder cancer in elderly patients. Prognostic outcomes and therapeutic strategies] |
| Q83964488 | [Chemotherapy for bladder cancer: 2012 Update. From AUO ("Arbeitsgemeinschaft Urologische Onkologie") and IABC ("Interdisziplinäre Arbeitsgruppe BlasenCarcinom")] |
| Q88115260 | [Guideline adherence - is more always better?] |
| Q53205542 | [Molecular classification of bladder cancer. Possible similarities to breast cancer]. |
| Q87610913 | [Molecular multimodal hybrid imaging in prostate and bladder cancer] |
| Q87140905 | [Morbidity, mortality, and overall survival after radical cystectomy: comparison of single-center results with the literature and a nomogram] |
| Q83654055 | [Patients' acceptance of urinary diversion. The pouch of Sisyphus] |
| Q83987314 | [Radical cystectomy - pro laparoscopic] |
| Q51790967 | [Radical cystectomy - pro robotic]. |
| Q87868391 | [Resecting hematogenous metastases: reasons against] |
| Q83326724 | [Treatment of bladder cancer. Value of radical prostate-sparing cystectomy] |
| Q92650173 | lncRNA CASC11 promotes cancer cell proliferation in bladder cancer through miRNA-150 |
| Q64102246 | lncRNA TUG1 Promotes Cisplatin Resistance by Regulating CCND2 via Epigenetically Silencing miR-194-5p in Bladder Cancer |
| Q38737064 | mTOR inhibitors in urinary bladder cancer. |
| Q34350342 | miR-150 modulates cisplatin chemosensitivity and invasiveness of muscle-invasive bladder cancer cells via targeting PDCD4 in vitro |
| Q48225163 | miR-221/222 cluster expression improves clinical stratification of non-muscle invasive bladder cancer (TaT1) patients' risk for short-term relapse and progression |